The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance

Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. However, the disease will inevitably progress over time due to acquired resistance. Longitudinal...

Descripción completa

Detalles Bibliográficos
Autores principales: Kibirova, Albina, Mattes, Malcolm D., Smolkin, Matthew, Ma, Patrick C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873100/
https://www.ncbi.nlm.nih.gov/pubmed/31762748
http://dx.doi.org/10.1159/000503417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873100/
https://www.ncbi.nlm.nih.gov/pubmed/31762748
http://dx.doi.org/10.1159/000503417

Ejemplares similares